Fibrinolytic guidelines in diabetes.
Urokinase and streptokinase are the two fibrinolytics approved for clinical use. Streptokinase has the broader application, being used to treat deep vein thrombosis (DVT), pulmonary embolism (PE), arterial thromboembolism, and occluded arteriovenous shunts in renal dialysis. Bleeding, the most significant complication of fibrinolytic therapy, arises mostly from invaded sites and can be significantly reduced by minimizing venipuncture and other invasive procedures.
D000368:Aged; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D048909:Diabetes Complications; D004341:Drug Evaluation; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D011655:Pulmonary Embolism / Q000188:drug therapy*; D013300:Streptokinase / Q000009:adverse effects / Q000627:therapeutic use; D013923:Thromboembolism / Q000188:drug therapy*; D013924:Thrombophlebitis / Q000188:drug therapy; D014568:Urokinase-Type Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D006493:Heparin; D013300:Streptokinase; D014568:Urokinase-Type Plasminogen Activator